Irritable bowel syndrome: new and emerging treatments
- PMID: 26088265
- DOI: 10.1136/bmj.h1622
Irritable bowel syndrome: new and emerging treatments
Abstract
Irritable bowel syndrome is one of the most common gastrointestinal disorders in developed nations. It is characterized by abdominal pain, altered bowel habits, and bloating. Several non-pharmacological and pharmacological agents, which target the peripheral gastrointestinal system and central nervous system, are used to treat the syndrome. The individual and societal impact of investigating and managing the syndrome is substantial, and despite newer treatments, many patients have unmet needs. Intense research at many international sites has improved the understanding of pathophysiology of the syndrome, but developing treatments that are effective, safe, and that have tolerable side effects remains a challenge. This review briefly summarizes the currently available treatments for irritable bowel syndrome then focuses on newer non-pharmacological and pharmacological therapies and recent evidence for older treatments. Recent guidelines on the treatment of irritable bowel syndrome are also discussed.
© BMJ Publishing Group Ltd 2015.
Similar articles
-
Irritable bowel syndrome: new and emerging therapies.Curr Opin Gastroenterol. 2006 Mar;22(2):128-35. doi: 10.1097/01.mog.0000208461.84513.f3. Curr Opin Gastroenterol. 2006. PMID: 16462168 Review.
-
Irritable bowel syndrome: modern concepts and management options.Am J Med. 2015 Aug;128(8):817-27. doi: 10.1016/j.amjmed.2015.01.036. Epub 2015 Feb 28. Am J Med. 2015. PMID: 25731138 Review.
-
Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.Pharmacotherapy. 2015 Jun;35(6):613-30. doi: 10.1002/phar.1594. Epub 2015 May 27. Pharmacotherapy. 2015. PMID: 26016701 Review.
-
Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.Prescrire Int. 2009 Apr;18(100):75-9. Prescrire Int. 2009. PMID: 19585728
-
How can we achieve relief of bowel and abdominal symptoms for patients with irritable bowel syndrome with constipation?Expert Rev Gastroenterol Hepatol. 2013 Jul;7(5 Suppl 1):21-6. doi: 10.1586/17474124.2013.820046. Expert Rev Gastroenterol Hepatol. 2013. PMID: 23859757 Review.
Cited by
-
Comparison of the Gut Microbiota Disturbance in Rat Models of Irritable Bowel Syndrome Induced by Maternal Separation and Multiple Early-Life Adversity.Front Cell Infect Microbiol. 2021 Jan 14;10:581974. doi: 10.3389/fcimb.2020.581974. eCollection 2020. Front Cell Infect Microbiol. 2021. PMID: 33520732 Free PMC article.
-
Persistence of gastrointestinal symptoms in irritable bowel syndrome and ulcerative colitis: study protocol for a three-arm randomised controlled trial (SOMA.GUT-RCT).BMJ Open. 2022 Jun 14;12(6):e059529. doi: 10.1136/bmjopen-2021-059529. BMJ Open. 2022. PMID: 35701050 Free PMC article.
-
Novel perspectives on therapeutic modulation of the gut microbiota.Therap Adv Gastroenterol. 2016 Jul;9(4):580-93. doi: 10.1177/1756283X16637819. Epub 2016 Apr 4. Therap Adv Gastroenterol. 2016. PMID: 27366225 Free PMC article. Review.
-
Sildenafil normalizes bowel transit in preclinical models of constipation.PLoS One. 2017 Apr 27;12(4):e0176673. doi: 10.1371/journal.pone.0176673. eCollection 2017. PLoS One. 2017. PMID: 28448580 Free PMC article.
-
Microbial evolution and ecological opportunity in the gut environment.Proc Biol Sci. 2019 Nov 20;286(1915):20191964. doi: 10.1098/rspb.2019.1964. Epub 2019 Nov 20. Proc Biol Sci. 2019. PMID: 31744431 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources